Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Adam Zlotnick
Indiana University Bloomington, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Door Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Door Pharmaceuticals is looking to develop new antiviral drugs that disrupt virus assembly. This project is looking at the basic mechanisms of HBV assembly. There is a possibility that this project could find a new mechanism that could lead to a new way to disrupt assembly and provide Door another potential avenue to research for drug development. There are no products from the outside entity being used in this project.
The Structural Biology of HBV
Narrative 240 million people suffer from chronic Hepatitis B Virus infection (HBV); treatment with reverse transcriptase inhibitors, the standard of care, decreases viral load and improves liver condition but it rarely leads to a ?cure?, even after years of treatment. In this proposal we examine the basic science underlying reverse transcription: RNA organization, polymerase structure, polymerase activity, and DNA organization. By understanding the target of many antivirals, we can contribute to improving them and to developing new antiviral targets towards a cure for chronic HBV.
Filed on April 12, 2019.
Tell us what you know about Adam Zlotnick's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Adam Zlotnick filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Adam Zlotnick | Indiana University Bloomington | Conflict of Interest | Assembly Bioscience | $200,000 - $249,999 |
| Adam Zlotnick | Indiana University Bloomington | Conflict of Interest | Assembly Bioscience | Value cannot be readily determined |
| Adam Zlotnick | Indiana University Bloomington | Conflict of Interest | Assembly Pharmaceuticals, Inc | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.